

1. PERSONAL INFORMATION

- a) Name: Dr Ikram Ali Burney
- b) Age: 59 years
- c) Sex: Male
- d) Nationality: Pakistani
- e) Civil ID #: 62555756
- f) Marital Status: Married
- g) Children: Ayesha, Zain, Rayyan, Eiman
- h) Tel. #: +968 24413406 / 968 99861633

2. EMPLOYMENT INFORMATION – (current and previous including designation)

- a) **Current Position:** Senior Consultant in Medical Oncology
- b) Institution: Sultan Qaboos Comprehensive Cancer Care & Research Center
- c) Period: Aug 2021 – to date

- d) **Current position:** Visiting Faculty
- e) Institution: Panjwani Center of Molecular Medicine and Drug Research, International Center for chemical and Biological Sciences, University of Karachi, Pakistan
- f) Period: March 2018 – to date

- g) **Position held previously:**
 - a. Sept 2006-Aug 2021: Senior Consultant in Medical Oncology, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
 - b. Jan 03-Sept 2006: Consultant Oncologist, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
 - c. April 97- Jan 2003: Lecturer & Consultant Oncologist, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
 - d. Feb 99 – Nov 99: Honorary Clinical and research Fellow, Department of Medical Oncology, Southampton University Hospital NHS Trust, Southampton, UK.
 - e. May 95 – April 97: Instructor, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
 - f. July 92 – May 95: Resident in Medicine, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
 - g. Sept 88 – April 92: Studied for PhD, Royal Post-Graduate Medical School, University of London, UK, & Clinical Attachment, Department of Oncology, Hammersmith Hospital, London UK
 - h. Sept 87 – July 88: Studied for MSc in Experimental Pathology & Toxicology, Royal Post-Graduate Medical School, University of London, UK
 - i. July 86 – July 87: Internship in Medicine (6 months) and Surgery (6 months), Liaquat Medical College hospital, Jamshoro & Hyderabad, Sindh, Pakistan

3. QUALIFICATIONS:

- Institution: Liaquat Medical College, University of Sindh, Pakistan
- Period: 1979 - 1986
- Major field of study: Medicine
- Highest Degree/Certification: MBBS

- Institution: Royal Postgraduate Medical School, University of London
- Period: 1987-1988
- Major field of study: Experimental Pathology & Toxicology

- Highest Degree/Certification: MSc
- Institution: Royal Postgraduate Medical School, University of London
- Period 1988-1992
- Major field of study Oncology
- Highest Degree/Certification: PhD, April 1992

4. MEDICAL PRACTICE LICENSES (specify country and dates)

Pakistan (Pakistan Medical & Dental Council – PMCD) No 12103-S

5. AWARDS AND RECOGNITION

1. *Certificate of Distinguished Research Paper*. Furrukh M, Kumar S, Zahid KF, Al-Shamly HS, Al-Jabri **Burney IA**, Al-Moundhri MS. Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital. Sultan Qaboos Univ Med J. 2017 Aug;17(3):e301-e308. **18th University Day, Sultan Qaboos University May 2, 2018**
2. *Certificate of Distinguished Research Paper*. Dobretsov S, Tamimi Y, Al-Kindi MA, **Burney I**. Screening for Anti-Cancer Compounds in Marine Organisms in Oman. Sultan Qaboos Univ Med J. 2016; May;16(2):e168-74. **17th University Day, Sultan Qaboos University May 3, 2017**
3. *Appreciation Certificate*. Sultan Qaboos University Hospital, on the occasion of the **Annual Hospital day, in recognition of outstanding performance. April, 2017**
4. *Certificate of Distinguished Research Paper*. Tamimi Y, Al Harthy S, Al Haddabi I, Babiker H, Al Moundhri M, **Burney IA**. The p53 status in an Omani cohort with diffuse large B cell lymphoma. Sultan Qaboos Univ Med J. 2014; 14(1):e50-8. **15th University Day, Sultan Qaboos University May 3, 2015**
5. *Appreciation Certificate*. Sultan Qaboos University Hospital, on the occasion of the **Annual Hospital day, in recognition of outstanding performance. Feb, 2014**
6. *Certificate of Academic Excellence*. Sultan Qaboos University, on the occasion of the 13th University day, in recognition of the **outstanding performance in teaching during the year 2012-13, May 2, 2013**
7. *European Certification in Medical Oncology*, European Society of Medical Oncology, Switzerland 2003, 2004
8. Received *Faculty Development Award* for the year 1998 – 1999 from the Aga Khan University for sub-specialty training in U.K. , 1998
9. Received a *Fellowship* to attend a course “Risk Assessment Summer School” (RASS) in Visby, Sweden in August ‘98. The fellowship was awarded by the International Union of Toxicology, 1998
10. *Overseas Research Students (ORS) Award* for the year 1990-91. This scheme is administered by the committee of Vice-Chancellors and Principals of the Universities of the United Kingdom and the award is given on the basis of outstanding merit and research potential, 1991
11. Received an *Overseas Training Scholarship* for four years 1987-91. This was awarded by the Ministry of Science and Technology of the Government of Pakistan after an open competition, 1987
12. Received a *Silver Medal* for obtaining **2nd position** in the final professional MBBS (Liaquat Medical College). 1986

13. Received a *Shield of Honor* for obtaining distinction in Ophthalmology.1986
14. Received a *Certificate of Merit* at the conferment of degree of MBBS. 1986

6. TEACHING

a) Scheduled undergraduate and postgraduate classroom teaching

- Phase II
 - Response to Infection and Pathobiology, Semester 1 1 Lecture and 2 Tutorials (ca 160 students)
 - Research methodology, Semester 2, 1 lecture 1 tutorial 40-50 students
 - Clinical Nutrition, Semester 3, 1 Tutorial (ca 120 students)
 - Integrated Module 1, Semester 2, 1 lecture
 - Integrated Module 2, Semester 3, 1 lecture, 2 Case discussions (ca 40 students)
 - Integrated Module 3, Semester 4, 1 lecture, 6 Case discussions (ca 75 students)
- BMS Curriculum
 - Biology of Cancer, 3 Lectures and 2 Tutorial (25 students)
- Phase III
 - Evidence based Medicine (RCTs) - Junior Clerkship (40 students x 3 times/year)
 - Medical errors and disclosure, Senior Clerkship, (20 students x 6 times / year)
 - Facilitate student-led seminar Senior Clerkship (10 students x 6 times / year)
- OMSB residents (15-20 residents)
- Postgraduate Master's and PhD students at ICCBS, Karachi, Pakistan
 - Precision Medicine in Oncology – a 1 credit course – delivered to 30 students
Master's and PhD at the International Center for Chemical and Biological sciences,
University of Karachi, Karachi, Pakistan

b) Bedside, clinic, and laboratory teaching

- Senior clerkship Phase III 1-2 hours every week for 42 weeks in a year
- OMSB residents
- Interns and Senior House officers

c) Instruction in training programs:

- Supervise Research projects for phase II, semesters 2-4
- Lecture in Chemotherapy Administration Course (4-6 times per year) for Nurses
- Workshops - Teaching and Assessment in the New Curriculum for Faculty

7. SCHOLARLY ACTIVITIES

1. Publications with references as per Index Medicus Format.

1. Field SB; Needham S; Burney IA; Maxwell RJ; Coggle JE; Griffiths JR. Differences in vascular response between primary and transplanted tumours. Br J Cancer. 63: 723-6, 1991
2. Field SB; Burney IA; Needham S; Maxwell RJ; Coggle J; Griffiths JR. Are transplanted tumours suitable as models for studies on vasculature? Int J Radiat Biol. 60: 255-60, 1991.
3. Burney IA; Maxwell RJ; Griffiths JR; Field SB. The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. Br J Cancer. 64: 683-8, 1991.
4. Burney IA; Maxwell RJ; Griffiths JR; Field SB. Deuterium nuclear magnetic resonance imaging of the developmental pattern of tumour blood flow. EXS. 61: 357-61, 1992.

5. Field SB; Burney IA; Needham S; Maxwell RJ; Griffiths JR. From hydralazine to CGRP to man? *Int J Hyperthermia*. 10: 451-5, 1994.
6. Burney IA; Maxwell RJ; Field SB; McCoy CL; Griffiths JR. Effect of vasoactive drugs on tumour blood flow as determined by 2H nuclear magnetic resonance spectroscopy. *Acta Oncol*. 34: 367-71, 1995.
7. Burney IA; and Khurshid M. Severe Thrombocytopenia in a man with Prostatic Cancer *JPMA* 45:252-54, 1995.
8. Burney IA and Malik IA. Chemotherapy - induced non-Hodgkins' lymphoma - A case report. *JPMA*. 46:14-15. 1996.
9. Kakepoto GN; Bhally S; Khaliq G; Kayani N; Burney IA; Siddiqui T; and Khurshid M. Epidemiology of blood-borne viruses: A study of healthy blood donors in southern Pakistan. *South East Asian J Trop Med Hyg*. 27: 703-706, 1996
10. Islam MU; Burney IA and Khurshid M. All trans retinoic acid syndrome; Radiological features. *Acta Radiol*. 38:340,1997
11. Burney IA. Acute tumour lysis syndrome following treatment of Hepatocellular Carcinoma. *Southern Med J*. 91: 467-70, 1998.
12. Burney IA; Islam MU; and Khurshid M. Retinoic acid syndrome: A potentially fatal side effect of Retinoic acid therapy. *JPMA* 48:57-55,1998.
13. Siddiqui T and Burney IA; Doxorubicin Cardiomyopathy in lung cancer patients. *JPMA* 48: 142-5, 1998.
14. Burney IA; Kakepoto GN; Siddiqui T and Khurshid M. All trans retinoic acid in acute promyelocytic leukemia: case series and review of literature. *JCPSP* 8:17-19,1998.
15. Burney IA; Farooqui BJ; Siddiqui T; and Khurshid M. The spectrum of bacteriological infections in neutropenic patients: Effect on empiric antibiotic therapy. *JPMA* 48: 364-367, 1998.
16. Iqbal MP, Sultana F, Mehboobali N, Burney IA, Siddiqui T and Waqar MA. Multiple forms of dihydrofolate reductase in leukocytes of cancer patients with non-hematological malignancies. *Bangladesh J Biochem* 3: 45-52, 1998
17. Bhatti FN, Burney IA, Moid MI, and Siddiqui T. Bacterial Isolates from neutropenic febrile pediatric patients, and their sensitivity patterns to antibiotics. *JPMA* 48: 287-90, 1998.
18. Burney IA., Siddiqui I and Siddiqui T. Elevated CA-125 levels in Pulmonary tuberculosis. (Letter). *Cancer* 85: 755-6, 1999.
19. Adil SN; Burney IA; and Khurshid M. Autoimmune hemolytic anemia in visceral leishmaniasis. *JPMA* 49: 100-101, 1999.

20. Siddiqui t, Burney I, Khurshid M. High dose chemotherapy in Hepatocellular carcinoma. (Letter to Editor). Singapore Med J. 1999; 40(2)-124.
21. Burney IA, Kakepoto,GN, Qureshi KH, Chandna IE, Adil SN, Siddiqui T, Khurshid M. Use of Colony Stimulating Factors in Acute Myeloid Leukemia: A Case Control Study. Med Sci Res 28: 105-107, 2000
22. Iqbal MP. Burney IA, Mehboobali N, Sultana F and Siddiqui T. Increased levels of multiple forms of dihydrofolate reductase in peripheral blood leucocytes of cancer patients receiving hematopoietic colony stimulating factors. Exp Mol Med 32:84-87, 2000
23. Sharieff S, Burney IA, Salam A, Siddiqui T. Lack of correlation between alpha fetoprotein and tumor size in hepatocellular carcinoma. JPMA 51:123-4, 2001
24. Iqbal MP, Burney IA, Sultana F, Mehboobali N. Induction of white cell proliferation due to hematopoietic growth factors is associated with an increase in multiple forms of dihydrofolate reductase in non-neutropenic cancer patients. JPMA 51:68-71, 2001
25. Sharieff S, Burney IA, Salam A, Haq N and Siddiqui T. Radiological Features of Hepatocellular Carcinoma in Southern Pakistan. Tropical Doctor. 31:224-225, 2001
26. Burney IA, Jilani SM, Siddiqui T, Smego RA Jr. An algorithmic approach to the management of febrile neutropenia. Infect Dis J. 10 : 17-21, 2001.
27. Anwar A, Naseem S, Burney IA, Khurshid M. Nocardiosis in Cancer patients: Case series and review of literature. Infect Dis J. 10 : 23-25, 2001.
28. Burney IA, Khurshaidi N, Hussain T, Bhatti FN, Siddiqui T, Sophie Z, Complications of indwelling venous access devices in cancer patients: A single institution experience. JPMA, 51: 434-437, 2001
29. Adil SN, Burney IA, Kakepoto GN, Khurshid M. Epidemiological features of Aplastic anemia in Pakistan. JPMA, 51: 443-445, 2001
30. Burney IA, Iqbal MP, Islam N. Life threatening bone marrow suppression in a patient with rheumatoid arthritis on low-dose methotrexate. PJMR 40: 104-5, 2001
31. Burney IA, Tai JM, Shah S, Khurshid M. Acute Myeloid Leukemia following regression of Sarcoidosis: A case report. PJMR 41: 39-40, 2002
32. Sharieff S, Burney IA, Salam A, and Siddiqui T. Hepatocellular Carcinoma. JCPSP 12: 264-67, 2002
33. Siddiqui T, Burney IA, Kakepoto GN, Khurshid M, Salam A, Smego RA Jr. Lack of benefit of granulocyte macrophage granulocyte-colony stimulating factor in patients with febrile neutropenia. JPMA, 52:206-8, 2002

34. Zaki S, Burney IA, Khurshid M. Acute myeloid leukemia in children in Pakistan: An audit. JPMA, 52: 144-47, 2002
35. Siddiqui I, Bhally HS, Niaz Q, Burney IA. Tumor-induced Hypercalcemia- Predictors of early mortality. JPMA, 52: 361-4, 2002
36. Kakepoto GN, Burney IA, Adil SN, and Khurshid M. Long-term outcomes of acute myeloid leukemia in adults in Pakistan. JPMA, 52: 482-86, 2002
37. Noor A, Biyabani R, Burney IA, and Talati J. Granulomatous Prostatitis after intra-vesical BCG: A case report. JPMA, 52: 578-80, 2002
38. Gaffar AA, Haq TU, Pishori T, Burney IA. Role of biliary stenting in iatrogenic jaundice : A case report. JPMA, 52:536-7, 2002
39. Burney IA, Moatter T, Siddiqui T. Pathergy in T-cell Non-Hodgkin's lymphoma. J Roy Soc Med, 96: 127, 2003
40. Iqbal MP, Mehboobali N, Sultana F, Khan FB, Burney IA, Kakepoto GN. Effect of methotrexate and folinic acid on accumulation of iron in mice tissues. Medical Hypothesis 61:444-5, 2003
41. Usman M, Burney IA, Nasim A, Adil SN, Salam A, Siddiqui T, Khurshid M. Outcome of adult acute lymphoblastic leukemia: a single center experience. JPMA 53: 384-8, 2003
42. Burney IA, Salam A, Jat AA, Iqbal MP, Siddiqui T, Smego RA Jr. Comparison of Low-Dose versus Standard-Dose Colony Stimulating Factor in Patients with Chemotherapy-Induced Febrile Neutropenia. Oncology 65: 283-84, 2003
43. Burney IA, Salam A, Ghaffar AA, Khan BA, Qureshi S. Spinal cord compression secondary to malignancy: An audit from a single institution. Ind J Med Ped Oncol, 24: 13-16, 2003.
44. Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney IA, Rizvi A, Grant C. Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res. 9(4):226-31, 2003.
45. Alidina A, Gaffar A, Hussain F, Islam M, Vaziri I, Burney IA, Valimohd A, Jafri W. Survival Data and Prognostic factors seen in Pakistani Patients with Esophageal Cancer Ann Oncol 15: 118-22, 2004
46. Alidina A, Siddiqui T, Burney I, Jafri W, Hussain F, Ahmed M. Esophageal cancer – A review. J Pak Med Assoc 54(3): 136-41, 2004
47. Al-Ubaidi F, Burney IA. An adrenal problem in a young girl. Clinical Biochemistry, 6: 93-94, 2004

48. Khan MA, Siddiqui BK, Shamim A, Yosuf MA, Ahmed U, Zakiullah N, Burney IA. Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan. *J Pak Med Assoc.* Jul;54(7):357-60, 2004
49. Hamid SS, Burney IA, Abid S, Abbas Z, Shah s, Jafri W. Late presentation and high disease burden leads to poor prognosis of hepatocellular carcinoma in Pakistan: an eight-year retrospective analysis. *Journal of Gastroenterology and Hepatology.* 19():A795, Dec 2004
50. Al Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The prognostic significance of p53, p27(kip1), p21(waf1), HER-2/neu, and Ki67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study of 121 Arab patients. *J Surg Oncol.* 15;91(4): 243-52, 2005
51. Ahmed S, Burney IA, El-Nour IB. Kikuchi's Disease in a 9-year-old Girl: Case Report. *Ann Trop Paediatr*, 25: 219-221, 2005
52. Al Moundhri MS, Burney I, Al Bahrani B, Nirmala V, Al Madhani A, Al-Mawaly K, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients. *Oncology*, 70(2):90-6, 2006.
53. Al-Moundhri MS, Al Nabhani M, Al Bahrani B, Burney IA, Al Madhani A, Ganguly SS, Yahyayee SA, Grant CG. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. *Gastric Cancer.* 9(4):284-90, 2006.
54. Al-Moundhri MS, Al-Bahrani B, Burney IA, Nirmala V, Al-Madhani A, Al-Nabhani M, Thomas V, Ganguly SS, Grant CS. The clinico-pathological features, treatment and survival of gastric adenocarcinoma in Omani Arab patients. *Asia Pacific J Clin Oncol.* 2: 137-143, 2006
55. Sawhney S, Burney IA, Jain R. Pulmonary infarction: A rare case of adrenal carcinoma. *SQUMJ.* 7: 55-7, 2007.
56. Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, Tanira M. NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. *World J Gastroenterol.* 13(19):2697-702, 2007.
57. Burney IA, Nirmala V, Al Moundhri MS, Woodhouse NY. Nodular lymphocyte predominant Hodgkin's lymphoma presenting as severe hypercalcemia. *SQUMJ.* 7:247-251, 2007
58. Alsaadi K, Al-Dhuhli H, Hussain S, Burney I. Fused CT/Ga-67 SPECT for detection of pleural lymphoma. *SQUMJ.* 7:261-262, 2007
59. Ur Rehman J, Burney IA, Al Kindi SS, Raeburn S. Familial lymphoma in an Omani kindred with identical class II HLA type. *Leukemia and Lymphoma.* 49(7):1407-10, 2008.
60. Burney IA, Al Moundhri MS, Rizvi SAJ, Ganguly SS, Al Abri R, Ashrafi RA. Outcome as a measure of quality of care in Oncology: SQUH Experience. *SQUMJ.* 8:27-36, 2008

61. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, Ganguly SS. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. *World J Gastroenterol*. 2008 Jun 28;14(24):3879-83.
62. Burney IA, and Al Moundhri MS. Major advances in the treatment of cancer: what does a non-oncologist need to know. *SQUMJ*. 8:137-148, 2008.
63. Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Habsi H, Ganguly SS, Tanira M. Combined polymorphism analysis of glutathione S-transferase M1/G1 and interleukin 1 β (IL-1 β)/interleukin 1-receptor antagonist (IL-1RN) and gastric cancer risk in Omani population. *J Clin Gastroenterol*. 2009 Feb;43(2):152-6.
64. Ahmed S, Burney IA, Sawhney S, Al Moundhri MS. Gastric adenocarcinoma in association with Tuberos sclerosus. *SQUMJ*. 9: 75-78, 2009.
65. Mathew M, Sheikh S, Rao K, Burney IA, Sawhney S, Al Hamdani A. Metastatic Malignant Melanoma during pregnancy. *SQUMJ*. 9: 79-83, 2009.
66. Ahmed S, Al Kaabi J, Burney IA, Rizvi SAJ. Non-Hodgkin's lymphoma mimicking Polymyalgia rheumatica. *Oman Medical Journal* 23: 189-191, 2009
67. Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi AA, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population. *Mol Carcinog*. 48: 1170-76, 2009.
68. Mathew M, Burney IA, Al Hamadani A, Rao K. Bilateral breast metastases in a pregnant woman with disseminated cutaneous melanoma. *Indian J Cancer*. 46: 342-4, 2009.
69. Burney IA. The trend to seek a second opinion abroad amongst cancer patients in Oman: Challenges and opportunities. *SQUMJ*, 9: 260-63, 2009.
70. Al-Moundhri MS, Al-Khanbashi M, Al-Kindi M, Al-Nabhani M, Burney IA, Al-Farsi, A, Al-Bahrani B. Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. *World J Gastroenterol*. 2010 Jul 21;16(27):3432-6.
71. Al-Asmi A, Nandhagopal R, Jain R, Burney IA. Full blown picture of Wernicke's encephalopathy. *QJM*. 2010 Nov;103(11):891-2.
72. Burney IA, Author's response Re: The trend to seek a second opinion abroad among cancer patients in Oman. *SQUMJ*. 10: 277, 2010
73. Nandhagopal R, Al-Asmi A, Arunodaya GR, Jacob PC, Al-Azri F, Burney IA. Gliomatosis cerebri. *QJM*. 2011 Jul;104(7):619-20.
74. Burney IA. Book Review. *Cancer Chemotherapy and Biotherapy: Principles and Practice*

(Authors: Chabner BA, Longo DL), Published by Wolters Kluwer: Lippincott Williams and Wilkins. SQU Med J, 11: 426-427, 2011

75. Kumar S, Burney IA, Al-Ajmi A, Al-Moundhri MS. Changing trends of breast cancer survival in sultanate of Oman. J Oncol 2011;316243. 25.
76. Al-Mujaini A, Wali U, Ganesh A, Al-Hadabi I, Burney I. Ocular adnexal reactive lymphoid hyperplasia in children. Middle East Afr J Ophthalmol. 2012 Oct;19(4):406-9.
77. Burney IA, Al-Moundhri MS. From Transplant to Tablets: A paradigm shift in Oncology. Sultan Qaboos Univ Med J. 2012 Nov;12(4):402-5.
78. Burney AA, Memon S, Ghaffar A, Salam A, Aftab Z, Burney IA. Clinicopathological features and outcomes of gallbladder cancer in southern Pakistan. Medical Channel . 18(1), 17-19 2012
79. Qureshi A, Zahid, KF, Azzawi S, Burney IA. Osteosarcoma arising on a background of Paget's disease report of an unusual case. BMJ Case Reports 2013. doi:10.1136/bcr-2012-007770
80. Furrukh M, Burney IA, Kumar S, Zahid KF, Al-Moundhri M. Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma. Sultan Qaboos Univ Med J. 2013 Feb;13(1):3-18.
81. Ali A, Al Belushi BS, Waly MI, Al Moundhri MS, Burney IA. Dietary and lifestyle factors and risk of non-Hodgkin's lymphoma in Oman. Asian Pac J Can Prev. 2013;14(2):841-8.
82. Furrukh M, Al-Moundhri M, Zahid KF, Kumar S, Burney I. Customized, Individualized Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). Sultan Qaboos Univ Med J. 2013 May;13(2):202-17.
83. Burney IA, Al-Lamki N. Accreditation of Graduate Medical Education Programmes: One size fits all-or does it? Sultan Qaboos Univ Med J. 2013 May;13(2):198-201.
84. Burney IA, Al-Lamki N. Response to letter. Re: Accreditation of Graduate Medical Education Programmes: One size fits all-or does it? Sultan Qaboos Univ Med J. 2013
85. Lakhtakia R, Al Wahaibi K, Zahid KF, Malik KA and Burney IA. Solid pseudo-papillary neoplasm of pancreas: A review of the diagnostic dilemma and tumor behavior. Oman Med J. 2013 Nov;28(6):441-4
86. Qureshi A, Kumar S, Ismail SI, Al Kalbani M, Burney IA. c-kit negative Extra intestinal gastrointestinal stromal tumor with no detectable mutations: A rare case. J Solid Tumors. 2013; 3:25-9
87. Burney IA, and Al Moundhri MS. Lifestyle modification and cancer prevention: Another weapon in war against cancer. Int J Nutr Pharmacol Neurol Dis. 2014 4: 1-3

88. Tamimi Y, Al Harthy S, Al Haddabi I, Babiker H, Al Moundhri M, Burney IA. The p53 status in an Omani cohort with diffuse large B cell lymphoma. *Sultan Qaboos Univ Med J*. 2014; 14(1):e50-8. Epub 2014 Jan 27.
89. Iqbal MP, Burney IA. Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase. *Pak J Pharm Sci*. 2014; 27(2): 245-8
90. Burney IA, Furrakh M, Al Moundhri MS. What are our options in the fight against breast cancer. *Sultan Qaboos Univ Med J*. 2014; 14 (2): 35-37.
91. D'Souza, PC, Kumar S, Kakaria A, Al Sukaiti R, Zahid, KF, Furrakh M, Burney IA, Al Moundhri MS. Use of Port-a-cath in cancer patients: A single center experience. *J Infect Dev Ctries*. 2014 Nov 13;8(11):1476-82. doi: 10.3855/jidc.4155
92. Kumar S, Burney IA, Al Moundhri MS. Near Complete resolution of refractory, relapsed, metastatic Wilm's tumor in a young adult with bevacizumab containing chemotherapy. *J Coll Surg Phys Pak*. 2014 Mar; 24 Suppl 1:S71-2.
93. Al Kalbani M and Burney IA. The epidemics of obesity and cancer: no simple remedy. *Sultan Qaboos Univ Med J*. 2014; 14 (3): 149-151
94. Lakhtakia R, Burney IA. Medical History: A brief history of breast cancer Part III –Tumor biology lays the foundation for medical oncology. *Sultan Qaboos Univ Med J*. 2015 Feb;15(1):e34-8.
95. Kumar S, Burney IA, Al Moundhri MS. Endocrine therapy for breast cancer – A success story in all treatment settings. *Austin J Cancer and Clin Res*. 2015 2(4): 1038
96. Lakhtakia R, Burney IA. Medical History. A historical tale of two lymphomas: Part-1. Hodgkin Lymphoma. *Sultan Qaboos Univ Med J*. 2015; 15(2): 202-206
97. Kumar S, Burney IA, Farhan K, D'Souza PC, Al-Belushi M, Mufti T, Al-Meki W, Furrakh M, Al-Moundhri MS. Colorectal cancer: Patients Characteristics, Treatment and Survival in Oman - a single center study. *Asian Pac J Cancer Prev* 2015; 16(12): 4853-4858
98. Lakhtakia R, Burney IA. Medical History. A historical tale of two lymphomas: Part-2.Non-Hodgkin Lymphoma. *Sultan Qaboos Univ Med J*. 2015 15(3): 317-321
99. Lakhtakia R, Burney IA, Qureshi A, Al Azawi S, Al Badi H, Al Hajri S. Unveiling cancer. *Sultan Qaboos Univ Med J*. 2015 15(3): 405-410
100. Udayakumar A, Al- Bahri M, Burney IA, Al-Haddabi I. Follicular dendritic cell sarcoma: Complex cytogenetics findings with typical Ultrastructural, Immunophenotypical and histological features. *Sultan Qaboos Univ Med J*. 2015 15(3): 411-414
101. Tamimi Y, Gupta I, Al Moundhri MS, Burney IA. Micrometastatic circulating tumor

- cells; A challenge for an early detection and better survival rates. *J Carcinogen Mutagen.* 2015; 6:4 doi: 10.4172/2157-2518.1000229
102. Lakhtakia R, Burney IA. Medical History. Self experimenting physicians: Mavericks or Martyrs. *Sultan Qaboos Univ Med J.* 2015; 15(4): 401-404
103. Furrukh M, Burney I, Qureshi A, Lakhtakia R. Cancer of Unknown Primary Site: Not All is Lost!. *J Clin Diagn Res* 2015; 3: 115. doi:10.4172/2376-0311.1000115
104. Dobretsov S, Tamimi Y, Al-Kindi MA, Burney I. Screening for Anti-Cancer Compounds in Marine Organisms in Oman. *Sultan Qaboos Univ Med J.* 2016; May;16(2):e168-74.
105. Kumar S, Burney IA, Saparamadu PAM, De'Silva C, Disseminated Kaposi's Sarcoma in an Immunosuppressed Patient after Long-term Inhaled and Systemic Steroids therapy. *J Coll Phys Surg Pak. J Coll Physicians Surg Pak.* 2016 Nov;26(11):135-136. doi: 226..
106. Qureshi A, Gowri V, Burney I, Al Kalbani M. Papillary mesothelioma of peritoneum involving fallopian tube: A challenging case. *J Solid Tumors.* 2017; 7: doi: 10.5430/jst.v7n1p20.
107. Burney IA. Immunotherapy in Cancer: Incremental gain or a quantum leap (editorial). *Oman Med J.* 2017;. 32(1): 3-4.
108. Gupta I, Burney I, Al-Moundhri MS, Tamimi Y. Molecular genetics complexity impeding research progress in breast and ovarian cancers. *Mol Clin Oncol.* 2017 Jul;7(1):3-14. doi: 10.3892/mco.2017.1275.
109. Burney IA, Lakhtakia R. Precision Medicine: Where have we reached and where are we headed? (editorial) *Sultan Qaboos Univ Med J.* 2017 Aug;17(3):e255-e258. doi: 10.18295/squmj.2017.17.03.001
110. Furrukh M, Kumar S, Zahid KF, Al-Shamly HS, Al-Jabri Burney IA, Al-Moundhri MS. Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital. *Sultan Qaboos Univ Med J.* 2017 Aug;17(3):e301-e308. doi: 10.18295/squmj.2017.17.03.007.
111. Kumar S, Raouf ZR, Al Moundhri MS, Saparamadu PAM, Ibrahim SI, Al Kindy N, Burney IA. Massive gastrointestinal bleeding from choriocarcinoma of the ovary. *Oman Med J.* 2018 Nov;33(6):527-530. doi: 10.5001/omj.2018.96.
112. Al-Sharbati ZM ; Burney IA; Hallas C; Al-Farsi YM; Al-Farsi OA; Gupta I; Al-Moundhri M; Farrukh M; Abdulmunem E; Al-Bahrani B; El-Bouri M; Al-Adawi S. Prevalence of depression and anxiety among patients with cancer in two major hospitals in Oman: a cross-sectional survey. Accepted for publication
113. Boulassel MR, Al Qarni Z, Burney IA, Khan H, Al Zubaidi A, Al Naamani A, Al Hinai H, Al Badi A, Qureshi R, Panjwani V, Al Farsi K. Levels of regulatory T cells and

- invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma. *Mol Clin Oncol*. 2018 Dec; 9(6):677-682. doi: 10.3892/mco.2018.1732.
114. Zahid KF, Kumar S, Al Baimani K, Ahmed T, Al Ajmi A, Burney IA, Al Moundhri M. Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital. *Oman Med J*. 2019; 34(5): 412-419
115. Kumar S, Furrukh M, Al Baimani K, al Ajmi A, Burney IA and Al Moundhri MS. Outcomes of women with non-metastatic triple-negative breast cancer in Oman. *Sultan Qaboos Univ Med J*. 2019; 19(3): 209-216
116. Lakhatakia R, Burney IA. For whom the bell does not toll: the invisible saga of cancer caregivers. *Sultan Qaboos Univ Med J*. 2019; 4: 275-276.
117. Al Shaaibi R, Burney IA. Motives for medical tourism amongst cancer patients in Oman: A perspective from patient's point of view. *The Journal of Global Health at Columbia University* 2019; 9(1).
<http://www.ghjournal.org/motives-for-medical-tourism-amongst-cancer-patients-in-oman-a-perspective-from-patients-point-of-view/>
118. Malgundkar S, Burney I, Moundhri M, Al Kalbani M, Lakhtakia R, Okamoto A, Tamimi Y. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β -catenin activity in ovarian cancer. *BMC Cancer*. 2020; 20: 374. doi.org/10.1186/s12885-020-06900-7
119. Boulassel MR, Burney IA, Al wardy N, Habbal O, Al Rawas O. Students Perceived Benefits of Integrating a BSc in Health Sciences within a Medical Degree at Sultan Qaboos University. *Sultan Qaboos Univ Med J*. 2020; 20(2): 187-193
120. Kumar S, Burney IA, Satyapal S, Kunju J, Al Marhoon MS, Siddiqui KM. Clinicopathological features, treatment and outcomes of Omani patients with localized prostate cancer. *Arab J Urol*. 2020. DOI: 10.1080/2090598X.2020.1781386
121. Al Bahlani S, Burney IA, Al Dhahi B, Al Kharusi S, Al Kharousi F, Al Kalbani A, Ahmed I. Boswellic acid sensitizes gastric cancer cells to cisplatin-induced apoptosis via p53-mediated pathway. *BMC Pharamcol Toxicol* 2020; 21:64. <https://doi.org/10.1186/s40360-020-00442-1>
122. Al Naamani K, Al Hashmi Z, Al Siyabi O, Al Moundhri M, Al Bahrani B, Al Sinani S, Al Zakwani I, Omar H, Al Busafi S, Al Zauhaibi H, Al Mamamri A, Kamath BR, Al Kalbani A, Burney IA. Hepatocellular carcinoma in Oman: An analysis of 284 cases. *Sultan Qaboos Univ Med J*. 2020; 20(3): 316-322.
123. D'Souza PC, Kumar S, Kakaria A, Al Sukaiti R, Al Baimani K, Hamid RS, Mittal AK, Burney IA, Al Moundhri MS. Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman. *Sultan Qaboos Univ Med J*. 2021; 21(1): e103–e109

124. Malgundkar SH, Burney I, Al Moundhri M, Al Kalbani M, Lakhtakia R, Okamoto A, Tamimi Y. *E2F5 Promotes the Malignancy of Ovarian Cancer Via the Regulation of Hippo and Wnt Pathways*. *Genet Test Mol Biomarkers*. 2021 Mar;25(3):179-186.
125. Burney IA, Abdwani R, Al Hashmi K, Al Wardi N, Al Saadoon M. COVID-19 and the clinical phase of the MD curriculum: Challenges and the way forward. *Sultan Qaboos Med J*. 2021. 21(2): 191-194
126. Al Maqrashi Z, Burney IA, Al Sawafi Y, Taqi KM, Qureshi A, Lakhtakia R, Mehdi I, Al Bahrani B, Kumar S, Al Moundhri M. Clinico-pathological features and outcomes of gastrointestinal tumors (GIST) in Oman. *Sultan Qaboos Univ Med J*. 2021. 21(2): 237-243
127. Burney IA, Al Hadhrami A, Kakaria A. Complete response to Sorafenib in locally recurrent, unresectable aggressive fibromatosis. *Sultan Qaboos Med J*. 2021. 21(2): e327-328.
128. Labrague LJ, Al Sabei SD, AbuAlRub RF, Burney IA, Al Rawajfah O. Authentic leadership, nurse assessed patient events and quality of care: The mediating role of nurses' safety actions. *Journal of Nursing Management*. 2021. <https://doi.org/10.1111/jonm.13356>
129. Abdullah N, Tamimi Y, Dobretsov S, Balushi N, Shukeili J, Al Balushi H, Alkindi M, Hassan SI, Al Bahlani S, Tsang B, Burney IA. Malformin-A1 (MA!) sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis. *Molecules*. 2021. 26, 3624. <https://doi.org/10.3390/molecules26123624>
130. Al Sabei SD, AbuAlRub RF, Labrague LJ, Burney IA, Al Rawajfah O. The impact of perceived nurse's work environment, teamness, and staffing levels on nurse-reported adverse patient events in Oman. *Nursing Forum*. 2021. <https://doi.org/10.1111/nuf.12639>
131. Labrague LJ, Al Sabei SD, Al Rawajfah O, AbuAlRub RF, Burney IA,. Authentic leadership and nurses' motivation to engage in leadership roles: The mediating effects of nurse work environment and leadership self-efficacy. *Journal of Nursing Management*. August 2021. Doi.[10.1111/jonm.13448](https://doi.org/10.1111/jonm.13448)
132. Kumar S, Al Balushi M, Dsouza PC, Burney IA, Al Moundhri M. Beliefs and Perceptions about Cancer Diagnosis, Treatment Seeking and Decision-Making Behaviors among Omani Patients with Cancer: A Single Center Study. 2021. *J Relig Health*. Doi.org/10.1007/s10943-021-01381-9
133. Abdullah N, Al Balushi N, Hassan SI, Al Bahlani S, Dobrestsov S, Tamimi Y, Burney IA. Hymenialdisine is cytotoxic against cisplatin-sensitive but not against cisplatin-resistant cell lines. *Sultan Qaboos Med J*. 2021; 21(4): 632–634. <https://doi.org/10.18295/squmj.4.2021.049>
134. Al Saifee S, Al Adawi B, Burney IA. Patterns of Bacterial Isolates and their Resistance to Antibiotics in Patients with Chemotherapy-Induced Febrile Neutropenia at a University Hospital. *Oman Med J*. July 2021, 36(4):e290-e290

135. Al Hinai M, Gupta I, Lakhtakia R, Al Kalbani M, Burney I, Al Moundhri M, Okamoto A, Tamimi Y. Epigenetic Silencing of FBXW7 through Promotor Hypermethylation in Ovarian Cancer. *Genetic Testing and Molecular Biomarkers*. Accepted for publication
136. Burney IA, Al Sulaimi J, Al Kalbani M, Gowrie V, Zahid F, Kumar S, Furrukh M, Rizvi SG, Al Moundhri MS. Long-term outcomes of Pregnancy-Associated Breast Cancer: A Single Institution Experience. *Liaquat National Journal of Cancer Care* 2020; 2(2): 39-44.
137. Labrague LJ, Al Sabei SD, Al Rawajfah O, AbuAlRub RF, Burney IA, Interprofessional collaboration as a mediator in the relationship between nurse work environment, patient safety outcomes and job satisfaction among nurses. *Journal of Nursing Management*. October 2021. DOI:[10.1111/jonm.13491](https://doi.org/10.1111/jonm.13491)

2. Research projects (Unfunded):

1. **Principal investigator** “(Lymphoman-1) Clinico-pathological Features of Non-Hodgkin’s Lymphoma in Oman”. *Ongoing*. Interim analysis presented in Univ day SQU, 2005
2. **Principal investigator (SQU site)** Global Investigation of therapeutic decision in Hepatocellular Carcinoma and its treatment (MREC #393). Invited to participate in an International Multicenter Phase IV clinical Trial.
3. **Principal investigator:** Ikram A Burney, Harith Al Harthy. Determinants of seeking second opinion outside of Oman in suspected or newly diagnosed cancer patients in Oman: A qualitative study. SQU MREC
4. **Principal investigator** Ikram A Burney, Muneera Jaafri. Clinico-pathological features and outcomes of cancer of cervix in Oman. SQU MREC
5. **Principal investigator** Ikram A Burney, Jawaher Al Namani. Clinico-pathological features and outcomes of cancer of uterus in Oman. SQU MREC
6. **Principal Investigator** Ikram A Burney, Ali Al Mashni, Aziz Al Kathiri. Patient Perception of cancer Diagnosis in Sultanate of Oman. SQU MREC
7. **Principal Investigator** Burney IA, Al Majarafi, N Systolic dysfunction in patients receiving doxorubicin-based chemotherapy for DLBCL. SQU MREC
8. **Principal Investigator** Burney IA, Al AlSaifi, S. Patterns of bacterial isolated and their resistance in febrile neutropenic patients. SQU MREC
9. **Co-supervisor:** PhD project for Ms Kamla Salmani. Evaluation of the cytotoxic effects of 3-O-acetyl-11-keto- β -boswellic acid in ovarian cancer cells. I wrote the project Kamla is registered as a PhD student with Dr Mark D Evans. Oxidative Stress Group, Department of Cancer Studies &

Molecular Medicine; Department of Genetics, University of Leicester, UK. *Kamla has completed the PhD from University of Leicester.*

10. **Principal Investigator** Burney IA, Al Hatmi, S, Al Rawahi Z, Sharbati, Z, Boulassel MR. Prevalence of anxiety and depression in cancer patients at SQUH. SQU MREC

11. **Principal Investigator** Burney IA, Al Jabri A, Al Adawi M. Prevalence of comorbidities amongst patients with selected cancers. SQU MREC

12. **Principal Investigator** Burney IA, Boulassel MR, Absolute Lymphocyte-to-monocyte ratio (LMR) as a prognostic marker in diffuse large B cell lymphoma SQU MREC

13. **Principal Investigator** Burney IA, Al Kalbani M, Al Fizzari E, Al Ghafri S. Clinico-pathological features and outcomes of epithelial ovarian and endometrial cancers in Oman SQU MREC

3. Grants awarded:

1. **Principal investigator** “Comparison of different doses of Colony stimulating factors in febrile neutropenia and their mechanism of action in inducing cell proliferation”. Seed Money Grant, from Aga Khan University 1997-1999. (US \$ 10,000). Reported in *Oncology*, 2003

2. **Principal investigator** at AKUH site. “A randomized, open-label, multi-center, phase III study of 5-FU/Leucovorin with or without concomitant SU5416 in patients with metastatic colorectal cancer”. Sponsored by Pharmacia and Upjohn and SUGEN Pharma, 2001-2002 Reported in *ASCO* 2003

3. **Co-Investigator** “Characterization of genetic lesions in apoptosis regulating and proliferation control genes in diffuse large B-cell Non-Hodgkin’s lymphoma: Correlation with presenting clinical features and treatment outcomes”. University Research Council Grant from Aga Khan University for the year 2001-2002.

4. **Co-Investigator** “Phase III trial of ALIMTA vs Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who were previously treated with chemotherapy”. Participation in a multi-center trial, Sponsored by Elli-Lilly company, 2001-2002. Reported *J Clin Oncol* May 2004

5. **Principal investigator** (Lymphoman-2) Cyclophosphamide, pegylated liposomal doxorubicin, vincristine, prednisolone for the therapy of aggressive non-Hodgkin’s lymphoma in the elderly patients. Partly sponsored by Schering-Plough. *Ongoing*

6. **Principal investigator** (Lymphoman-3) Lymphomagenesis in developing countries: a study of patient-related, environment –related and disease-specific parameters in Oman. Ongoing (SQU grant RO 20,150)

7. **Co-Principal investigator** (Lymphoman-4) Role of dietary and lifestyle risk-factors on the

prevalence of non-Hodgkin's lymphoma in Oman. (DOPSAR grant RO 4,500).

8. **Principal investigator** (Lymphoman-5) Are cellular signaling pathways involved in the pathogenesis of virally associated lymphomas (SQU grant RO27,700)

9. **Principal investigator** (Lymphoman-6) Genetic polymorphisms of nutrient and inflammatory genes in diffuse large B cell lymphoma in Omani Arabs (RO2,000).

10. **Principal investigator** (Lymphoman-7) Prognostic and Predictive biomarkers in Diffuse Large B cell lymphoma. IG/MED/MED1/11/02 (RO10,000).

11. **Co-Investigator:** The prognostic role of tissue, serum and whole blood DNA global and site-specific promoter methylation in locally advanced breast cancer during neo-adjuvant chemotherapy treatment. (The Research Council of Oman)

12. **Principal investigator (SQU site)** Global Investigation of therapeutic decision in Hepatocellular Carcinoma and its treatment (MREC #393). Invited to participate in an International Multicenter Phase IV clinical Trial.

13. **Co- Principal investigator: (PI: Dr Sergey Dobretsov, CAMS, SQU):** Bioactive compounds from Omani marine organisms. (OR12,000)

14. **Principal investigator** Use of Honey for Chemotherapy and radiotherapy induced oral mucositis. (MREC #435)

15. **Principal investigator** A study of candidate biomarkers in epithelial ovarian cancer, and correlation with treatment outcomes. (IG/MED/MEDE/13/01) (OR3,000)

16. **Co-investigator** Mohammed R Boulassel, Ikram A Burney, Khalil Al Farsi, Salam Al Kindi, Sulaiman Al Hashmi, Murtada Al Khabouri, Amar Oukil, Alya Al Ansari. Understanding the cross talk among regulatory immune cells in lymphomas: A link to improve the efficacy of immunotherapeutic strategies. Internal grant from SQU.

17. **Co-investigator:** Yahya Tamimi, Mansour Al-Moundhri, Ikram Burney, Roseline Godbout, Moza Al-Kalbani, Ritu Lakhtakia. Identification of putative genes involved in early steps of epithelial ovarian cancer pathogenesis. HMTF OR 75,100 over 3 years

18. **Co-investigator:** Khawaja F Zahid, Ikram A Burney, Mansour Al Mouhdhri, Shiyam Kumar. Role of inflammatory biomarkers in early detection of Trastuzumab induced cardiotoxicity. SQU Internal Grant OR1000 MREC

19. **Co-investigator:** Khawaja F Zahid, Ikram A Burney, Mansour Al Mouhdhri. Biological subtypes of breast cancer in patients with brain metastases. Qatar HMC/AUB, US \$5000

20. **Co-investigator:** Al Bahlani S, Burney IA, Anticancer effects of boswellia Sacra (Frankincense) on ovarian cancer cells resistant to cisplatin-induced apoptosis. (IG/MED/16/01)

21. **Principal Investigator** Burney IA, Al Riyami M, Al Sayegh A, D'Souza P. PREDICT: Prevalence of BRCA1 and BRCA2 mutations in Ovarian Cancer patients in the Gulf region. Funded by Astra Zeneca, Building 27 Block D, Dubai Healthcare City (US\$5,500) (MREC 1441)
22. **Principal Investigator** Burney IA, Ahmed I, Dobretsov S, Tamimi Y, Al Bahlani S, Rinner U, Ahmed SI. High Grade Epithelial Ovarian Cancer: Overcoming Chemotherapy Resistance with Omani Marine Compounds. His Majesty's Trust Fund Grant.(OR75,000) (SR/MED/MEDE/17/01)
23. **Co-investigator:** Al Sabei, S, Burney IA. The Role of Hospital Work Environments on Enhancing the Quality of Patients' Care and Nurse Outcomes in the Sultanate of Oman (OR18,000). RC/RG-CON/FACN/18/01
24. **Co-investigator:** Rahman S, Waly M, Nanofibers from Date-Flesh and Date-Pits of Low Grade or Un-utilized Date Fruits: its preparation, characterization and functionality. HMTF.
25. **Principal Investigator** Burney IA, Usman A, Raniga S. CPZP034AIC04 - PARACHUTE: PAZopanib Real-world Assessment of Clinical effectiveness and safety in patients who have Undergone Treatment in different settings in advanced renal cell carcinoma; a prospective, non-interventional, observational study. Sponsored by Novartis Pharma AG. (US\$8550) (MREC 1555)
26. **Co-investigator:** Al Awaisi H, Al Balushi M, and Burney IA. Assessing the quality of life and exploring the experience of survivors of gynecological cancers in Oman. (OR 690). RF/MED/NURS/19/01

4. Books and chapters in books

1. Burney IA; Maxwell RJ; Griffiths JR; and Field SB. Clinical potential for the use of calcitonin gene-related peptide (CGRP) as a modifier of tumour blood flow. In, Radiation Research: A Twentieth Century Perspective. Chapman JD, Dewey WC, and Whitmore GF. (eds). Volume 1: 38,29. Academic Press Inc, San Diego. 1991.
2. Field SB; Burney IA; Needham S; Maxwell RJ; Coggle JE; and Griffiths JR. Relevance of transplanted tumour models for studies relating to tumour vasculature. In, Radiation Research: A Twentieth Century Perspective. Chapman JD, Dewey WC, and Whitmore GF. (eds). Volume 1:38,30. Academic Press Inc, San Diego. 1991.
3. Burney IA. Clinical potential of reduction in tumour blood flow. PhD thesis. 1992.
4. Burney IA; Farooqui BJ, and Khurshid M. Bacterial Isolates in neutropenic patients: A retrospective analysis. In basic and applied research in health care and social development (eds) Shah BH; Gilani A; Qureshi AF; and Orchard C. PP183-187,1997.
5. Burney IA; Hasan I, Hyder J, Salahuddin I, and Malik IA. Neoadjuvant chemotherapy for locally advanced head and neck cancers. In basic and applied research in health care and social development (eds) Shah BH; Gilani A; Qureshi AF; & Orchard C. PP202-205,1997
6. Burney IA; Mead GM. Chemotherapy of testicular cancer. *In* Treatment options of urological

cancer (editor: Jonathan Waxman) Blackwell Science. 305-316, 2002

7. Burney IA. Prevention of Common Cancers of the Female Genital Tract. *In* Bioactive Components, Diet and Medical Treatment in Cancer Prevention (eds) Mostafa Waly, Mohammed Shafiur Rehman, Springer pp161-185, 2018

5. Abstracts published:

1. Field SB; Burney IA; Needham S; Maxwell RJ; Coggle JE; and Griffiths JR. Differences in the response of the vasculature in primary and transplanted tumours. *Br J Radiol.* April:322;1990.
2. Burney IA; Maxwell RJ; Griffiths JR; and Field SB. Modification of tumour blood flow by hydralazine, prazosin and calcitonin gene-related peptide (CGRP), assessed by nuclear magnetic resonance spectroscopy. *Int J Radiat Biol.* 60:254;1991.
3. Burney IA; Maxwell RJ; Griffiths JR; and Field SB. Clinical potential for CGRP as a modifier of tumour blood flow. *Int J Radiat Biol.* 60:939;1991.
4. Burney IA; Favis G; Sorathia A; Siddiqui T. Predictors of development of pneumonia during chemotherapy induced febrile neutropenia in patients with acute myelogenous leukemia. *Blood.* 1997
5. Siddiqui T; Ahmed R; Burney IA; Sorathia A; Favis G. Sequential use of GM-CSF and G-CSF in chemotherapy induced neutropenic fever. *Blood.* 1997.
6. Iqbal MP, Burney IA, Sultana F, Mehboobali N, Siddiqui T, and Khurshid M. Putative role of colony stimulating factors in cell proliferation through induction of forms of dihydrofolate reductase. *Br J Hematol* 102: 26, 1998.
7. Burney IA, Mead GM, and Sweetenham, JW. PACE-BOM salvage prior to high dose therapy and autologous stem cell transplantation (ASCT) for aggressive non-hodgkin's lymphoma (NHL): An active well-tolerated out-patient regimen. *Br J Cancer* 80(S2): 54, 1999.
8. Burney IA, Pellatt JC, Mead GM, Sweetenham JW. PACE-BOM: Effective, out patient salvage chemotherapy for relapsed aggressive Non-Hodgkin's lymphoma prior to high dose chemotherapy. *Blood* 94(10): 173, 1999.
9. Burney IA, Salam A, Iqbal MP, Khurshid M, Siddiqui T. A comparison of two dose-levels of colony stimulating factors in high-risk febrile neutropenia. *Int J Hematol* 72 (S1): 138-9, 2000
10. Iqbal MP, Burney IA, Sultana F, Mehboobali N. Effect of half the conventional doses of GM-CSF and G-CSF on multiple forms of dihydrofolate reductase and duration of neutropenia. *Int J Hematol* 72 (S1): 139, 2000
11. Burney IA, Sheikh MU, Salam A, Jilani SM, Kakaepoto GN, Khurshid M. A prognostic model for ALL. *Blood*, 2001

12. Burney IA, Salam A, Orakzai, SH, Orakzai RH and Sharieff S. Predicting prognosis in unresectable Hepatocellular carcinoma. Br. J Cancer, 86(S1): S46, 2002
13. Burney IA, Rashid S, Salam A, Siddiqui T. Does prognostic score apply to Pakistani patients with Hodgkin's disease. Acta Oncol, 13(S5): 123, 2002
14. Burney IA, Islam M, Nadeem S, Adil SN, Kakepoto GN, Alidina A, Jilani SM, Siddiqui T, Khurshid M. Outcomes of cancer in Adults in Pakistan. JPMA 52(S1): S11, 2002
15. Saeed O, Ali SS, Salam A, Burney IA, Causes and outcomes of tumor-induced hypercalcemia. JPMA 52(S1): S18-19, 2002
16. Ali SS, Saeed O, Salam A, Burney IA. Prognostic factors determining outcomes in malignant spinal cord compression. JPMA 52(S1): S20, 2002
17. Tai JM, Burney IA. Malignant pleural effusion: Causes and outcomes. JPMA 52(S1): S21, 2002
18. Memon S, Lashari I, Islam M, Khan MM, Muzaffer S, Burney IA. Outcomes of primary gastric lymphoma: Single center experience from southern Pakistan. JPMA 52(S1): S22-23, 2002
19. Shamim A, Karim B, Shahwali, Ahmed U, Yousuf MA, Zakiullah N, Khan MA, Alidina A, Burney IA. Febrile neutropenia in cancer patients in a tertiary care medical center in Pakistan: Microbial spectrum and outcomes. JPMA 52(S1): S23, 2002
20. Lashari I, Memon S, Siddique U, Gareeb M, Islam M, Burney IA. Outcomes of Non-hodgkin's lymphoma in Pakistan: Use of international prognostic index. JPMA 52(S1): S23-4, 2002
21. Ahmed A, Tasneem Z, Naseemuddin, Islam M, Burney IA. Outcomes of patients treated for o-small cell lung cancer: A retrospective analysis. JPMA 52(S1): S27, 2002
22. Gaffar A, Danish N, Salam A, Nadeem S, Burney IA. Outcomes of unresectable carcinoma of Gall bladder. JPMA 52(S1): S28-9, 2002
23. Alidina A, Gaffar a, Islam M, Burney IA, Siddiqui T, Ahmed M, Jafri W. Survival data on Pakistani patients with esophageal cancer. JPMA 52(S1): S30-1, 2002
24. Ansari TZ, Burney IA, Islam M, Furrakh M, Kamal S. Patient's perceptions about cancer diagnosis and chemotherapy: Results from an ongoing prospective study. JPMA 52(S1): S35, 2002
25. Badar S, Burney IA. Using baloon infusion pump technique in administering chemotherapy in ambulatory patients – A cost-effective approach. JPMA 52(S1): S37-8, 2002
26. Hussain M, Burney IA, Alidina A, Niamatullah N. Local experience with the use of

Trastuzumab in metastatic breast cancer. JPMA 52(S1): S41-2, 2002

27. Alidina A, Burney IA, Vaziri I, Siddiqui T, Gaffar, A. Survival data on Pakistani patients with oesophageal cancer. Proc Am Soc Clin Oncol 1192, 2003
28. Al Moundhri MS, Al Bahrani B, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The prognostic significance of p53, p27kip, p21waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study. Proc Am Soc Clin Oncol. 23(16S): 320s (abs), 2005
29. Burney IA, Ahmed S, Rehman J, Al Kindi S, Nirmala V, Al Moundhri MS Presentation of non-Hodgkin's lymphoma in Oman: a prospective study from a single institute. Annals of Oncol, S5: 342(abs), 2005
30. Burney IA. Unresectable non-small-cell lung cancer: chemotherapy and beyond. J Pak Med Assoc. 55(S1), 2005
31. Al Moundhri MS, Al Bahrani B, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The patterns of clinico-pathological features, management and survival of gastric adenocarcinoma in the Sultanate of Oman. 2nd international congress on GI Oncology, Santorini Island Greece, June 2005
32. Al Moundhri MS, Al-Nabhani M, Al Yahyai S, Ganguly SS, Burney I, Al Bahrani B, Grant C. Interleukin 1 β gene polymorphisms and gastric adenocarcinoma in Oman – preliminary results. Europ Can Conf Paris, France, Oct 2005
33. Al-Moundhri MS, Al-Bahrani B, Al-Nabhani M, Burney I, Al-Kindy M, Ganguly SS, Tanira M The prognostic significance of IL-1-B and GST T1/M1 polymorphisms in non-metastatic gastric cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 4084, 2006
34. Burney IA, Ganguly SS, Al Kindy S, Al Moundhri MS. Outcomes of Hodgkin's lymphoma in Oman. Ann Oncol 17: S9: 212(abs) 2006.
35. Mathew M, Tazneem S, Rao K, Burney IA, Rizvi A, Sawhney S, Ramadani F. Metastatic Malignant melanoma during pregnancy – A case report. SQU Med J. 8: 112(abs), 2008.
36. Burney IA, Moundhri MS, Rizvi AJ, Ganguly SS, Abri R, Ashrafi RA. Outcome as a measure of quality of care in Oncology: SQUH Experience. SQU Med J. 8: 245(abs), 2008.
37. M. S. Al-Moundhri, M. Al-Nabhani, I. Burney, A. Rizvi, A. Al-Farsi, and B. Al-Bahrani. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms in an Omani population. ASCO Meeting Abstracts 27: 4568, 2009
38. Burney IA, Al Sawai BS, Dawood AA, Babiker H, Al Moundhri MS. Association of polymorphisms in cytokine genes with Diffuse Large B cell lymphoma and its outcomes in

Omani Arabs. Eur J Cancer 7: 566, (abs9222) 2009

39. Burney IA. Lymphoma is different here. Abstracts of Advanced General Medicine Conference. Sultan Qaboos Univ Med J. 10: 293, 2010

40. Burney IA, “Teaching Patient Safety in the Undergraduate Medical Curriculum”. Proceedings of First International conference on Patient Safety. Jan 31-Feb2, 2011, Sultan Qaboos Univ Med J.

41. Burney IA, “The impact of research on healthcare outcomes in Cancer practice”. Proceedings of 3rd International Conference on Quality Management. Feb 6-8, 2012, Sultan Qaboos Univ Med J.

42. Burney IA, “Assessment in the Clinical phase of outcome-based curriculum. Proceedings of 3rd International Conference on Medical Education. Mauritius, Oct 4-6, 2013

43. Burney IA, Al Sulaimi J, Al Kalbani M, Gowri V, Mathew M, Zahid F, Kumar S, Furrugh M, Al Moundhri MS. Pregnancy associated breast cancer: a report of outcomes of pregnancy and breast cancer from an arab country 18th meeting of the European Society of Gynecological Oncology, Liverpool, UK, 19-22 Oct, 2013.

44. Burney IA. Pregnancy-associated breast cancer. Proceedings of International Conference on Gynecology. Sultan Qaboos University, Muscat Oman, Dec 3-6, 2013, Sultan Qaboos Univ Med J. 2014; 14 (2): xxx

45. Kamla KSA AlSalmani, Marcus S. Cooke, Ikram A. Burney, Mark D. Evans. Evaluation of the cytotoxic effects of 3-O-acetyl-11-keto- β -boswellic acid in ovarian cancer cells. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A43.

46. Al-Khanbashi M, Caramuta S, Al-Ajmi A, Al-Hadabi I, Kumar S, Dsouza PC, Zahid KF, Malik KA, Furrugh M, Burney IA, Al Bahrani BJ, Lui W and Al-Moundhri MS. Dynamic changes of miRNA and cancer related proteins (CRPs) expression during neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC). *Journal of Clinical Oncology*, 2013 ASCO Annual Meeting Abstracts. Vol 31, No 15_suppl (May 20 Supplement), 2013: e22099

47. Tamimi Y, Burney IA, Al Kalbani M, Lakhtakia R, Godbout R, Al Moundhri M. Identification of putative genes involved in early steps of epithelial ovarian cancer pathogenesis [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-TECH-1130.

48. Almutawea L, Al Kalbani M, Lakhtakia R And Burney IA. Patterns of Presentation and Outcomes of Germ Cell Tumors in Women in Oman. 2014 Research publications and research profile. United Arab Emirates University. P125

49. Kamla Al Salmani, Esther Moss, Don Jones, Raj Patel, Ikram Burney, Mark D. Evans.

Frankincense as a Potentially Novel Therapeutic Agent in Ovarian Cancer. 27th Lorne Cancer Conference 2015. At: Mantra Lorne, Lorne, Victoria, Australia. DOI. 10.13140/2.1.1016.2241

50. Al Salmani K, Moss E, Jones D, Patel R, Burney I, Evans MD. Frankincense as a Potentially Novel Therapeutic Agent in Ovarian Cancer. NCRI Cancer Conference abstracts. A82. Nov 2015. abstracts.ncri.org.uk

51. Burney IA, Al Wardy N, Sadoon M, Al Zedjali, F, Gujjar A, Al Balushi K. Quantification of educational workload in a university hospital and medical school. . #9N4 (2728). AMEE abstract book 2017

52. Al Hinai M, Gupta I, Lakhtakia R, Al Kalbani M, Burney I, Al Moundhri M, Okamoto A, Tamimi Y. Epigenetic silencing of FBXW7 through promoter hypermethylation in ovarian cancer. *J Microbiol Gen.* 2017; 2(2) suppl: 18

53. Tamimi Y, Al Hinai M, Gupta I, Lakhtakia R, Al Kalbani M, Burney I, Okamoto A, Al Mounthri M. Epigenetic silencing of FBXW7 through promotor hypermethylation in ovarian cancer. *Eur J Human Genet.* 2018; 26, 742-742

54. Al kalbani M, Al Shueli A, Al Moundhri MS, Burney IA, Tamimi Y. Differential expression of SOCS3 gene and its putative role in the pathogenesis of epithelial ovarian cancer. *Int J Gynecol Can* 2019; 29 (Suppl 3):A114.3-A115. IGCS Annual 2019 Meeting Abstract.

55. Al Kindi F, Al Kalbani M, Al Moundhri M, Burney I, Tamimi Y. Differential expression of SOCS2 gene and its putative role in ovarian cancer. *Int J Gynecol Cancer* 2019; 29 (Suppl 4), A430-A430

56. Hanif S, al Moundhri MS, Burney IA, Tamimi Y. EP867 Tumor suppression by FAT4 occurs by acting through retinoblastoma pathway in epithelial ovarian cancer. *Int J Gynecol Can.* 2019; 29(4): A471.1-A471. 29 (Suppl 4):A525.1-A525.

57. Al Balushi N, Abdulla N, Al Dhahli B, Hasan I, Dobretsov S, Al Bahlani S Tsang B, Tamimi Y, Burney I. Gallic acid exhibits lower cytotoxicity on normal ovarian cells than cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. *Int J Gynecol Cancer* 2019; 29 (Suppl 4), A430-A430

58. Abdulla N, Al Balushi N, Al Dhahli B, Hasan I, Dobretsov S, Al Bahlani S Tsang B, Tamimi Y, Burney I. The effect of malforminal on cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. *Int J Gynecol Cancer* 2019; 29 (Suppl 4), A426-A42.

59. Azribi F, Abdou E, Dawoud E, Ashour A, Kamal A, Alsayed M, Burney I. Prevalence of BRCA1/2 mutations in patients with ovarian cancer in the Gulf region: The PREDICT study. *Ann Oncol.* 2020; 31:S296-297

60. Al Balushi M, Al Awaisi, H, Burney IA. Quality of life of survivors of gynecological cancers in Oman. Presented as an e-poster, ESCGO, Nov, 2021

6. In-service training undertaken (e.g. CPR, ACLS, etc.)
 1. Basic Life Support AKUH February 1993
 2. Advanced Cardiac Life Support, AKUH February 1993
 3. Risk Assessment Summer School, Sweden, August 1998.
 4. Statistics. Southampton University Hospitals NHS Trust, UK, 1999
 5. Bio-ethics in Research Workshop AKUH, July 2001
 6. Basic Life Support & Advanced Cardiac Life support AKUH July-Aug2001
 7. The certificate course in health professions education. SQUH Oct 2004
 8. Faculty training workshop on IDEAL system for supporting delivery of Formative online assessments. SQUH, Dec 2004
 9. ESMO Scientific and Educational Conference. Budapest, Hungary, June 2005
 10. First Palliative Care Workshop Ministry of Health Muscat, Oman, June 19-20, 2005
 11. First workshop on investigating medical errors, Quality management department, SQUH, Muscat, Oman 2006
 12. ICH GCP Guidelines Workshop, Muscat Oman, Nov 2006
 13. Lead Auditor course, The IRCA certified training course leading to IQCS certification, in compliance with the ISO 9000:2000 series. Course no: IATCA 18021 certified by IRCA. SQUH, Muscat, Feb 24-28, 2007
 14. Eighth Advanced Medicine Symposium, SQU, March 4-5, 2007
 15. The first workshop on Medical Ethics, Nizwa Hospital, Nizwa, Nov 1, 2007
 16. Fire awareness. SQUH. Muscat, Oman, Nov 2007
 17. Basic Life Support, SQUH, Muscat, Oman, Dec 2007
 18. The Clinical Ethics Workshop, as part of First International Conference of Quality Management in Health care SQUH, Muscat, Jan 18, 2008
 19. Symposium on Medical Ethics from Islamic Perspective, College of Applied Sciences, Nizwa, Oct 30, 2008
 20. Facilitator at 'Basic Clinical Research Designs and Health Informatics workshop. SQU, Jan 11, 2009.
 21. The New courses: How to achieve a clinically oriented curriculum, SQU, Muscat, Oman, April 13-14, 2009
 22. Curriculum Development and Assessment. SQU, Muscat, Oman, April 22-23, 2009
 23. Continuous Assessment of Clinical Skills and Professional Behavior. SQU, Muscat, Oman, Feb 18, 2010
 24. Advanced General Medicine Conference. SQU, Muscat, Oman, Feb 21-22, 2010.
 25. Construction of Integrated Questions, CoM&HS, SQU, Muscat, May 1, 2010
 26. Leukemia and Lymphoma. ESO Advanced Course, Ascona, Switzerland. June 12-14, 2011
 27. Program for Advancement of treatment in Hepatocellular carcinoma (PATH), Barcelona, Spain, Oct 2-4, 2011
 28. Research Methodology workshop. SQU, Muscat, Oman, Nov 12-15, 2011
 29. Assessment of Clinical Competence, SQU, Muscat, Oman, Feb 14-16, 2012
 30. Six Sigma and Lean Thinking Course, SQUH, Muscat, Oman, Feb 8-11, 2015.
 31. Teaching Skills for Educators. Organized by International Health Innovation Network, University of Dundee. SQU, Muscat, Oman, April 6-7, 2015
 32. Student Assessment Workshop (participated and facilitated) CoM&HS, SQU, Oct 1-3, 2016
 33. Scholarship in education. One day workshop delivered by Prof David Cook, organized by Medical Education Unit, CoM&HS, SQU, Dec 4, 2016

34. WHO Patient Safety Curriculum Guide Workshop organized by Director General Quality Assurance, Ministry of Health, Muscat, Oman, April 24-25, 2017
35. Basic Life Support, Armed Forces, Hospital, Nov 23, 2021

8. SERVICE (clinical and non-clinical)

- a) Organization: Working as a Senior Consultant in Medical Oncology, Department of Medicine, SQUH
 - a) Clinical Workload; The Medical Oncology Unit at SQUH is one of the two units in the Sultanate, where all the cancers are treated. At SQUH, there are 5 consultants (One Professor; Two Senior Consultants), and 4 Registrars. Around 500-600 new cases of cancer are seen annually. The average daily work load is 25-30 in-patients, 12-15 patents receiving chemotherapy in the day care unit, and 60-80 patients in the weekly out-patient clinic. The clinical service includes:
 - a. Direct patient care, both in in-patient (average 6-8 patients daily) and out-patients (average 22 patients every weekly clinic)
 - b. Patient care meetings:
 - i. Morning meeting Sun-Wed 8.00 – 9.30 AM
 - ii. Grand round Thursday 10.00 AM – 1.00 PM
 - iii. Tumor Board Sunday 12.00 – 2.00 PM
 - iv. Radiology meeting Wednesday 12.00 – 1.00 PM
 - b) Supervision of residents and Interns
 - c) Chairman of Cancer Care services Team and a former Department al Quality Representative (DQR) at the time of ISO 9001:200 Certification
 - d) Weekly meetings on quality improvement and assurance
 - a. Policies:
 - i. Patient admission
 - ii. Patient discharge
 - iii. Inter-departmental referrals
 - iv. Intra-departmental referrals
 - v. Clinical Privileges
 - b. Protocols:
 - i. Management of febrile Neutropenia
 - ii. Management of Spinal Cord Compression
 - iii. Management of Superior Vena Caval Obstruction
 - iv. Management of Acute Tumor Lysis Syndrome
 - v. Management of Hypercalcemia
 - vi. Management of Chemotherapy-induced Nausea and Vomiting
 - e) Technical reports:
 - a. Job Descriptions for Physicians, Nurses, Administrative and Technical staff at SQUH (2006-2007)
 - b. Financial Cost of cancer care at SQUH (2015)
 - c. Expert report on MD curriculum at Oman Medical College (2018)

9. ADMINISTRATION

- a) Project supervision:

b) Supervision of junior colleagues:

PhD

Co-supervisor: Kamla Al Salmani, Supervisor: Dr. Mark D. Evans, Lecturer, Oxidative Stress Group, Dept. Cancer Studies & Molecular Medicine, University of Leicester, Robert Kilpatrick Clinical Sciences Bldg, Leicester Royal Infirmary, UHL NHS Trust, Leicester, LE2 7LX., United Kingdom

Anticancer effect of *Boswellia Sacra* on Epithelial Ovarian Cancer: A First Step Study Towards Understanding Molecular Pathways and Mechanisms of Drug Resistance.

Co-supervisor: Nada Ali, Supervisor, Dr Yahya Tamimi, Asst Professor, Department of Biochemistry, CoM&HS, SQU, Oman.

High Grade Epithelial Ovarian Cancer: Overcoming Chemotherapy Resistance with Omani Marine Compounds.

Co-supervisor: Shika H Malgundkar, Dr Yahya Tamimi, Asst Professor, Department of Biochemistry, CoM&HS, SQU, Oman.

The hidden function of LncRNA in ovarian cancer: an emerging key role in gene regulation.

Co-supervisor: Wajid Zaman, Supervisor, Dr Muddassar, Asst Professor, Panjwani Center for Molecular Medicine and Drug Research. International Center for Chemical and Biological Sciences (ICCBS). University of Karachi.

Evaluation of Peroxisome Proliferator-Activated Receptor Modulator against Lung Cancer, and *in vivo* Chemotherapy-Induced Cognitive Impairment

Co-supervisor: Zaiab Abbasi, Supervisor, Dr Muddassar, Asst Professor, Panjwani Center for Molecular Medicine and Drug Research. International Center for Chemical and Biological Sciences (ICCBS). University of Karachi.

Pharmacological Evaluation of Peroxisome Proliferator-Activated Receptor Modulator in Breast Cancer *in vitro*, and Chemotherapy-Induced Cognitive Impairment *in vivo*

MSc:

1. Co-supervisor: **Buthaina Al Belushi**,
 - a. Supervisor: Dr Amanat Ali, Associate Professor, College of Agriculture and Marine Sciences, SQU, 2007-2008
 - b. "Role of dietary and lifestyle risk-factors on the prevalence of non-Hodgkin's lymphoma in Oman"
2. Co-supervisor: **Badriya Al Sawaei**,
 - a. Supervisor: Prof Hamza Babiker, Department of Biochemistry, CoM&HS, SQU, 2008-2009.
 - b. "Genetic polymorphisms of nutrient and inflammatory genes in diffuse large B cell

- lymphoma in Omani Arabs”
3. Co-supervisor **Sheikha Al Harthy**,
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2010-11.
 - b. “Mutations in p53 gene in Diffuse Large B Cell Lymphoma”
 4. Co-supervisor: **Zoya Shaikh**,
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2014-15.
 - b. “Mutation Spectrum of BRIP1 gene in Breast Cancer”.
 5. Co-supervisor: **Fatma Al Kindi**
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2016-2018.
 - b. ”Differential Expression of *SOCS2* gene and Its Putative Role in Ovarian Cancer Pathogenesis”
 6. Co-supervisor: **Asma Ali Al Shueli**
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2016-2018.
 - b. “Differential expression of *SOCS3* gene and it s putative role in the pathogenesis of epithelial ovarian cancer ”.
 7. Co-supervisor: **Shika Hanif Malgundkar**
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2017-2019.
 - b. “The effect of siRNA mediated silencing of *FAT4* and *E2F5* genes in Ovarian cancer cell lines”
 8. Co-supervisor: **Alaa Mohammad Samara**
 - a. Supervisor: Dr Yahya Tamimi, Department of Biochemistry, CoM&HS, SQU, 2020-2021.
 - b. “The Cross-Talk between the Forkhead Box C2 (FOXC2) Gene and Breast Cancer Genes 1 and 2 (BRCA1 & BRACA2) in Epithelial Ovarian Cancer”

OMSB Residents:

9. Supervisor: **Dr. Harith Al Harthy**.
 - a. Determinants of seeking second opinion outside of Oman in suspected or newly diagnosed cancer patients in Oman: A qualitative study.
10. Supervisor: **Dr Said Al Saifi**,
 - a. Bacterial isolates and patterns of resistance to antibiotics in febrile neutropenic patients at SQUH, 2015-2018.
11. Supervisor: **Nasser Al Majrafi**,
 - a. Systolic dysfunction in patients receiving doxorubicin-based chemotherapy for DLBCL, 2015-2018.

Undergraduate Students:

12. Supervisor (Ameera Al Kindi), Phase II student, “Is there an association between Hodgkin’s Lymphoma and Diabetes Mellitus” SQU 2010-11
13. Supervisor (Omaira Al Ismaily), Phase II student, “Is there an association between non-Hodgkin’s Lymphoma and Diabetes Mellitus” SQU 2010-11
14. Supervisor (Al Shayma), Phase II student, “Association between dietary and life style factors and breast cancer” SQU 2011-12
15. Supervisor (Fatma Al Belushi), Phase II student, “Association between dietary and life style factors and gastro-intestinal tract cancers” SQU 2011-12
16. Supervisor (Latifa Al Mutawea), Phase II student, “ Clinico-pathological features and

- outcomes of germ cell tumors at SQUH” SQU 2012-2013
17. Supervisor (Munnera Al Jaafari), Phase II student, “ Clinico-pathological features and outcomes of cancer of the cervix in Oman. 2013-2014
 18. Supervisor (Jawaher Al Naamani), Phase II student, “ Clinico-pathological features and outcomes of cancer of the uterus in Oman. 2013-2014
 19. Supervisor (Fatma Al Qassabi), Phase II student, “ Clinico-pathological features and outcomes of cancer of the Ovary in Oman. 2013-2014
 20. Supervisor (Raya Al Yahyae), Phase II student, “ Clinico-pathological features and outcomes of non-Hodgkin’s Lymphoma in Oman. 2013-2014
 21. Supervisor (Noora), Phase II student, “The role of dietary antioxidants on the biomarkers of oxidative stress and antioxidants and nutritional status of breast cancer patients. 2013-2014
 22. Supervisor (Ali Al Mashani). Phase II student, “Perceptions about the diagnosis of breast Cancer in Oman”. 2014-2015
 23. Supervisor (Aziz Al Kathiri). Phase II student, “Perceptions about the diagnosis of Prostate Cancer in Oman”. 2014-2015.
 24. Supervisor (Somaya Al Hatmi), Phase II students. Prevalence of depression in adult patients newly diagnosed to have cancer using HADS scale, 2015-2016.
 25. Supervisor (Zainab Al Rawahi), Phase II students. Prevalence of depression in adult patients newly diagnosed to have cancer using CESD scale, 2015-2016.
 26. Supervisor (Mariya Al Adawi), Phase II student. Prevalence of metabolic syndrome in adult patients with non-Hodgkin lymphoma, 2016-2017.
 27. Supervisor (Anisa Al Jabri), Phase II student. Prevalence of metabolic syndrome in patients with endometrial cancer, 2016-2017.
 28. Supervisor (Alla Khalaf Hamdan Al-Issaei), Phase II student. A prospective descriptive study of satisfaction of cancer patients attending Medical Oncology out-patient clinics at SQUH, 2017-2018.
 29. Supervisor (Arwa Essai), Phase II student. A descriptive study of satisfaction of cancer patients admitted to the medical oncology services at the Sultan Qaboos University Hospital (SQUH), 2017-2018.
 30. Supervisor (Jawaher Al Fori), Phase II student. Absolute Lymphocyte-to-monocyte ratio (LMR) as a prognostic marker in diffuse large B cell lymphoma (SQUH), 2018-2019.
 31. Supervisor (Shahd Al Ghafri and Ethar Al Fizzari), Phase II students. Clinico-pathological features and outcomes of ovarian and uterine cancers in Oman (SQUH), 2019-2020.

c) Co-ordination or participation in unit or departmental activities

1. Chairman, Departmental Curriculum Committee, 2010 - 2013
2. Chairman, Departmental Research Committee 2008 – 2011
3. Deputy Chairman, Education Committee, 2008 – 2013
4. Member, Departmental CME Committee, 2008 – 2011
5. Member, Departmental Clinical Services Committee 2008 - 2010
6. Member, Departmental promotions committee 2006 – 2010
7. Chairman, Departmental Budget Committee SQUH 2005 – 2008
8. Member, Clinical Services Committee, co-ordinator for in-patient services and protocol management SQUH 2005 – 2008
9. Member, Departmental Research Committee, Medicine 2005 – 2007
10. Co-ordinator 5th year clinical teaching SQU 2004 – 2005

11. Co-ordinator Clinical Skills module SQU 2004 –2005
12. Co-ordinator Communication skills module SQU 2004-2005
13. Member of task-force for departmental website (SQUH), 2003 -2004
14. Member Budget Committee (SQUH) 2003 - 2005
15. Member, Research Committee (AKU) 2000-2002
16. Member, Management Review Committee (AKU)2001 - 2003
17. Member, Intern and Residents Committee (AKU)2001 – 2003

d) Curriculum development:

1. Chairman, Curriculum Committee, CoM&HS, SQU, June 2014 – Aug 2021
2. Deputy Chairman, College Curriculum committee, SQU, 2012- June 2014
3. Member, College Examination Committee, 2010-to date
4. Chair, Phase III sub-committee for Clinical exams 2013 – June 2014
5. Co-ordinator, phase III of New Curriculum, SQU, Nov 2007 – June 2014
6. Member, Hematology/Locomotion Module – Problem Based Learning (AKU) 2002 - 2003
7. Member, Neoplasia and Multi-system Module – Problem Based Learning (AKU) 2002 - 2003
8. Member, Clinical Curriculum Committee – Problem Based Learning (AKU) 2002 – 2003
9. Chairman, Clinical Skills Committee, AKU. 2002 - 2003

e) Committees leadership and membership:

1. Member, College Advisory Board, March 2017 – Dec 2019
2. Member of the Budget Committee, CoM&HS April 2017 – Dec 2020
3. Chairman, Text book Committee, CoM&HS, SQU Nov 2014 – Dec 2020
4. Member, College Development and Strategic Planning Committee, CoM&HS SQU Feb 2015 – Aug 2021
5. Chairman Clinical Privileges Committee SQUH 2013 – March 2014
6. Member, Medical Research Committee, SQU, Jan 2012 – March 2015
7. Member, Task force to write Chemotherapy Policy for SQUH, 2011 – to date
8. Member, Hospital Ethics Committee, SQUH, 2010 – 2016
9. Member, Hospital Promotion and Change of Status Committee, SQUH, 2010 – Nov 2016
10. Member organizing Committee. Chemotherapy Administration Course, SQUH, Muscat Oman.
11. Associate Editor, SQUMJ, 2008 – to date
12. Member, Antibiotics Use Committee, SQUH, 2007 - 2008
13. Chairman, SQUH Job Description Committee, SQUH 2006 -2008
14. Member, Medical research and Ethics committee COMHS, SQU 2006-2008
15. Member, Task force for hospital medical staff credentials, SQUH 2006-2007.

f) Quality management

1. Chairman, Cancer Care Services Team (CCS-t), Sept 2014 – April 2017
2. Certified Lead Auditor, SQUH, Feb 2007 to date
3. Departmental Quality Representative, for ISO 9001:2000 certification and quality management SQUH 2004 to 2008
4. Chairman, CRM group SQUH 2005 –2006
5. Member, Quality Circle – Reducing delays for day-care chemotherapy patients, AKU, 2002 - 2003

10. INVITED SPEAKER/PROFESSORSHIP

1. "What should be the end-points for the use of cytokines: An evidence-based study from AKUH". Developing perspectives in hematology-oncology: A dialogue. Bhurban 1997.
2. "Medical management of tumor induced osteolysis" 12th international congress of Pakistan Orthopedic association. Bhurban 1997.
3. "Medical issues related to death and dying" in the PGME Conference at AKU May '98.
4. "Medical Management of Bone Secondaries". One-day cancer symposium, Karachi, 1998.
5. "Current Status of BMT/PBSCT in your Country" Invited by the 6th Congress of Asian-Pacific Bone Marrow Transplantation Group, Taipei, Taiwan November 98'.
6. "Outcomes of Acute Lymphoblastic Leukemia in Pakistani Adults". One-day cancer symposium, Karachi 2000.
7. "Current Status of BMT/PBSCT in Pakistan" Invited by the 7th Congress of Asian-Pacific Bone Marrow Transplantation Group, Bangkok, Thailand, Nov 2000.
8. "Clinical practice guidelines for the management of testicular tumors in Pakistan". Cancer Research Group meeting, Islamabad, April 2001.
9. "Metabolic bone diseases: Hypercalcemia of malignancy". 16th annual symposium of the Pakistan Society of Physicians, Karachi, May 2001.
10. "Management of patients with neutropenia and fever". Research trends, clinical issues and the challenges of treating infections. Karachi, May 2001.
11. "Prevention and early detection of lung cancer" WHO sponsored workshop, JPMC, Karachi, Dec 2001.
12. "Current medical therapy for HCC" 18th Gastroenterology congress, Karachi, May 2002
13. "The Psychological aspects of management of blood cancer", Living with blood Cancer, Jang Forum Aug 2002
14. "Recent Advances in the management of Diffuse Large B Cell Lymphoma" 9th Annual Cancer Conference of Pakistan Society of Clinical Oncology, Karachi, Dec 2002
15. "Recent Advances in the endocrine treatment of breast cancer", Dubai, UAE, Aug 2003
16. "Metastatic disease and palliative measures". Update on Gastric malignancies. Salalah, Oman Sept 2003
17. "Palliative care services at SQUH". WHO sponsored workshop, Muscat, Oman, June 2005
18. "Unresectable non-small cell lung cancer: chemotherapy and beyond", 3rd International Oncology and Nuclear Medical Oncology conference, Karachi, Pakistan July 2005
19. "Chemotherapy in Head and Neck cancers" Al Nahda Hospital, Muscat Oman May 2006.
20. "New standards of care in the management of NHL. First International Conference". Towards New Standards of Care for Cancer Treatment. Under the Auspices of National Oncology Center. Muscat, Oman. Feb 2007
21. "Recent advances in the management of non-Hodgkin's Lymphoma". First International Student conference. Oman Medical College, Sohar, Oman. March 26-28, 2008.
22. "Informed Consent". National Symposium on Medical Ethics with an Islamic Perspective. Nizwa Hospital. Nizwa, Oman, Oct 30, 2008.
23. "Tailoring treatment for Hodgkin's Lymphoma". 2nd International Radiation Oncology Conference. Organized by Royal Hospital, MoH. Muscat, Oman Feb 26, 2009.
24. "Etiogenesis of non-Hodgkin's lymphoma in Oman / developing countries. Hematology conference 2009. Karachi, Pakistan Oct 15-18, 2009.
25. "Management of Metastatic Renal Cell Carcinoma: SQUH experience", Experts consensus meeting, Dubai, Nov 13, 2009.
26. "DLBCL in Oman and developing countries: A propos of a different disease". 15th Annual

- Cancer Conference, Pakistan Society of Clinical Oncology, Lahore, Pakistan, Nov 21, 2009.
27. "Management of Triple Negative Breast cancer". 15th Annual Cancer Conference, Pakistan Society of Clinical Oncology, Lahore, Pakistan, Nov 22, 2009.
 28. "Measurement of Quality in Oncology practice". Liaquat National Hospital Symposium, Karachi, Pakistan, Dec 12, 2009.
 29. "Lymphoma is different here". Advanced General Medicine Symposium jointly organized by Royal College of Physicians of the UK, Sultan Qaboos University and Ministry of Health, Oman. Muscat, Oman, Feb 20-22, 2010.
 30. "nab Paclitaxel –It's Uses and Indications" Registration meeting in Karachi, Pakistan, April 5, 2010.
 31. "Breaking Bad News: Challenges that remain to patient and their families". Collaborative nursing conference. Delivering Quality, Serving Communities, Nurses leading chronic care. SQU, Muscat, April 28, 2010.
 32. "p53 mutations in Diffuse Large B cell Lymphoma". 16th Annual Cancer Conference of the Pakistan Society of Clinical Oncology. Karachi, Pakistan, March 11-13, 2011
 33. "An update on the management of primary CNS lymphoma" 10th Shaukat Khanum Cancer Conference, Lahore, Pakistan. Nov 19, 2011.
 34. "Genetic Heterogeneity in Epithelial Ovarian Cancer". 1st International conference on consanguinity and genetics, Muscat, Oman, March 18, 2012
 35. "Management of non-small cell lung cancer". 4th International Oncology Conference. Muscat, Oman. May 27, 2012
 36. Burney IA Kumar, S, Zahid KF, Furrukh M, Al Moundhri MS. Reasons for early discontinuation of primary tyrosine kinase inhibitors in metastatic renal cell carcinoma: a single institution experience. Africa and Middle east Oncology conference. Budapest, Hungary, Oct 20-21, 2012
 37. "Can lifestyle modification be used to prevent and treat cancer". World Cancer Awareness day. Muscat, Oman Jan 31, 2013
 38. "Sero-prevalence of hepatitis viruses in Oman: Implications for treatment. Oman Pharmaceutical Conference 2013. organized by Oman Medical College, Muscat, Oman April 17, 2013
 39. "Debate: Switch therapy is preferred in adjuvant hormone therapy in postmenopausal women – Contra speaker". 5th Muscat International Oncology Conference. Muscat, Oman, Sept 17-19, 2013
 40. "Carcinoma of Unknown primary Site: Treatment". 5th Muscat International Oncology Conference. Muscat, Oman, Sept 17-19, 2013
 41. Renal Cell Carcinoma in Oman: opportunities and challenges. Pazopanib launch meeting, organized by GSK, Nov 13, 2013
 42. Update on the management of Anaplastic Large Cell Lymphoma. 12th Shaukat Khanum Cancer Symposium, Lahore, Pakistan. Nov 28-dec 1, 2013
 43. Management of Pregnancy-associated Breast Cancer. 1st International Gynecology Conference, Muscat, Oman, Dec 3-6, 2013
 44. A case of melanoma. Abraxane Standalone symposium 2014. Dubai, April 18, 2014
 45. The impact of research on outcome of cancer patients. 6th Muscat International Oncology & 3rd Oman Cancer Association conference. Muscat, Oman, Nov 30-Dec 1, 2014
 46. Outcomes of cancer patients when busy clinicians are also active in research. 18th Annual Symposium. Aga Khan University, Karachi, Pakistan. Feb 24-26, 2015
 47. Systolic dysfunction after doxorubicin based chemotherapy in DLBCL. 18th Annual

- Symposium. Aga Khan University, Karachi, Pakistan. Feb 24-26, 2015
48. Teaching Ethics to MD students in an Integrated, Outcome-based Curriculum. 1st International Bioethics Conference. SQU, Muscat, Oman, March 8-10, 2015.
 49. Management of Unresectable malignant melanoma. BMS symposium. 7th Muscat International Oncology Conference, Muscat, Oman, Sept 11-15, 2015
 50. Management of relapsed epithelial ovarian cancer. 20th meeting of the Pakistan Society of Clinical Oncology. Karachi, Pakistan. Oct 9-11, 2015
 51. VTE prophylaxis in cancer patients. 20th meeting of the Pakistan Society of Clinical Oncology. Karachi, Pakistan. Oct 9-11, 2015
 52. Evidence-based management of high grade epithelial ovarian cancer. 1st International conference on obstetrics and gynecology, Muscat, Oman, Sept 21-23, 2016
 53. Update on the management of metastatic cancer of the cervix. 1st Qatar Gynecological Malignancy Symposium and Workshop. Doha, Qatar. April 17-18, 2017
 54. Teaching Patient Safety in Medical Curriculum at CoM&HS. Introducing WHO-EMRO Patient Safety curriculum Guide into Colleges / institutions. Two day Workshop arranged by DGQAC, MoH, Muscat, Oman April 24-25, 2017
 55. Quantification of education workload in a university hospital and medical school. AMEE, Helsinki, Finland, Aug 26-30, 2017
 56. Screening marine organisms for anti-cancer activity, 6th symposium of the Molecular Medicine and Drug Research, International Center for Chemistry and Biological Sciences, Karachi University, Karachi, Pakistan, Nov 6-9, 2017
 57. Precision Medicine in Oncology. Precision oncology and Immunotherapy in Oncology. One-day symposium organized by Mohammed bin Rashid University, Dubai Health City, Dubai, UAE, Jan 28, 2018
 58. Anti-Oxidants as adjuvant to Cancer Treatment: What is the Evidence ? Symposium organised by Department of Nutrition and Food Sciences, College of Agriculture and Marine Sciences, SQU, Muscat, Oman, April 24, 2018
 59. Precision Medicine in Oncology: An Illusion or a Reality. International Center for Chemistry and Biological Sciences, Karachi University, Karachi, Pakistan, Nov 6-8, 2018
 60. Precision Medicine in Oncology: Urgently needed, but where are we. The 8th Annual meeting of the middle-eastern association for cancer research. SQU, Muscat, Oman, Dec 8-9, 2018
 61. Value of Undergraduate Research and Challenges of Integrating Research into Courses and the Curriculum Structure. Undergraduate research workshop, SQU, Muscat, Oman, Dec 13, 2018
 62. Precision Medicine in Cancer Care. 1st National Scientific conference, Pak China Conference Hall, Islamabad, Pakistan, Dec 15-16, 2018
 63. Best of ASCO 2019: Gynecological malignancies. Society of Medical Oncology of Pakistan. Lahore, Pakistan. Aug 30-31, 2019
 64. Optimizing TKI treatment in RAI-R DTC; Webinar arranged by Bayer Pharma. June 2, 2020
 65. Alk positive lung cancer: A case from Oman. Webinar organized by Astra-Zeneca. Sept 7, 2020
 66. Best of ASCO 2020: SOLO-2 study, Organized by Tawam hospital, Sept 2020
 67. In Search of Improving Outcomes Across the Continuum of Ovarian Cancer. COMSTECH Webinar. July 30, 2021
 68. How to treat in clinic MDT a case of newly diagnosed ovarian cancer: Practice vs Challenges. GCC Women's cancer summit. Organized by Saudi Oncology Society. Virtual conference. Sept 11, 2021

1. CME/CONFERENCES

1. "Current Advances in Cancer Management" at the Sindh Employees Social Security Institute Doctors Training Course in Karachi, August '1996.
2. "Medical issues related to death and dying" in the PGME Conference at AKU May '98.
3. "Clinical practice guidelines for the management of testicular tumors in Pakistan". Cancer Research Group meeting, Islamabad, April 2001.
4. "Bone metastasis: diagnosis and management", Update in Hematology/Oncology, Sept 2002
5. "Fever of Undetermined Origin: Neoplastic Fever", CME for GPs, AKUH, Sept 2002
6. "Surveillance, prevention and early detection of Cancer", CME for GPs, AKUH, Sept 2002
7. "New developments in the management of Non-small cell lung cancer." Cancer awareness program for Physicians, organized by Cancer Society of Multan, Multan, Oct 2002
8. "Oncological emergencies", Continuing medical education update, Nizwa hospital Auditorium, Nizwa, Oman, March 2005
9. "Chemotherapy in Head and Neck cancers" Al Nahda Hospital, Muscat Oman May 2006.
10. "Management principles of Breast cancer". CME for the pharmacists at the Oman Medical College. Muscat, Oman. April 2007.
11. "Overview of the management of Hodgkin's lymphoma". CME organized by the Medical Oncology unit of the Royal Hospital. Muscat, Oman. May 2007.
12. "Post-transplant lymphoproliferative disorders". 2nd National Nephrology Update. Sohar Hospital Auditorium. Sohar, Oman. May 2007.
13. "Do not Resuscitate" CME organized by Nizwa Hospital, Nizwa, Oman, Oct 2007
14. "Oncological emergencies" Update on Medical Emergencies. CME organized by Ibra Hospital, Ibra, Oman, Feb 20-21, 2008.
15. "Ethics Consultative Services" Workshop for OMSB residents, SQU, Muscat, Oman Oct 4, 2009
16. "Integration of Clinical Sciences". First New Curriculum Retreat. Muscat, Oman, Dec 10, 2009.
17. "Phase III in the New Curriculum", Curriculum and research Retreat, CoMHS, Crowne Plaza Hotel, Muscat, Oman, March 3, 2011.
18. "Teaching and Assessment in Junior Clerkship in Phase III". Curriculum Retreat, Muscat, Oman, Jan 12, 2012
19. "Neo-adjuvant chemotherapy and Adjuvant Radiotherapy" CME Surgery Nizwa Hospital, Oman, March 1, 2012.
20. Meeting Etiquettes, Knowledge Forum, SQUH, Oman, May, 2012
21. Relapsed Epithelial Ovarian Cancer: Sorting through the options. Oncology Forum, Dec 13, 2012
22. Update on phase III. Curriculum retreat, SQU. Crowne Plaza, Muscat, Oman, March 14, 2013
23. Examination Blueprinting, 1st retreat of the BMS program, SQU, Crowne Plaza, Dec 21, 2013
24. Role of Medical Oncology. Update on Gynecological Oncology, organized by Oman Society of Obstetrics & Gynecology, Muscat, Oct 24, 2014
25. Workplace based assessment. 12th CHPE course, SQU, Muscat, Oman, Feb 21, 2015.
26. Cancer Scene in Oman. Nurses day, May 2015
27. Non-Hodgkin Lymphoma: What the health care professionals need to know. Patient Awareness seminar. 7th Muscat International Oncology Conference, Muscat, Oman, Sept 11-15, 2015
28. A novel method of improving patient outcomes. ED seminar. SQUH. Nov 10, 2015

29. A review of non-Hodgkin lymphoma in Oman. College of Engineering Research seminar, March 29, 2016
30. Team-based learning. A two-hour workshop for School teachers at Pakistan School Seeb, Muscat, Oman. Sept 3, 2016
31. Workplace based assessment. 13th Student Assessment Workshop, SQU, Muscat, Oman, Sept 2016.
32. Advancing treatment approach in advanced Ovarian Cancer, Standalone symposium, Muscat, Oman. May 2, 2017
33. How to write learning objectives. 14th CHPE course, SQU, Muscat, Oman, Oct 23,24, 2017
34. Workplace based assessment. 14th Student Assessment Workshop, Oct 31-Nov 2, 2017 SQU, Muscat, Oman,
35. Critical Appraisal of studies on prognosis, Department of Continuous Professional development, Ministry of Health, Oman, Nov 14, 2017.
36. Management of high grade epithelial ovarian cancer. Symposium organized by Astra-Zeneca. Muscat, Dec 19, 2017
37. Prevention of Cancer. A public awareness seminar. Organized by Pakistan Social Club. On the eve of world Cancer Day 2018. Feb 3, 2018
38. Critical Appraisal of studies on prognosis, Department of Continuous Professional development, Ministry of Health, Oman, Feb13, 2018.
39. Tackling Ovarian Cancer across the Continuum of Care. Research seminar at the College of Agriculture and Marine sciences. SQU. Feb 27, 2018
40. Recurrent Ovarian Cancer: How to optimize your treatment sequence? Two-day symposium organized by Astra Zeneca, Dubai, UAE, April 27- 28, 2018
41. High Grade Epithelial Ovarian Cancer: *Overcoming Chemotherapy Resistance with Omani Marine Compounds*. Annual report on the work on HMTF grant. 18th University day. CoM&HS May 6, 2018
42. A *tryst* with Management of Melanoma. Symposium organized by Merck. Muscat, Oman, May 6, 2018
43. Clinical Short Case Assessment. Enhancing Learning through Clinical Assessment. Oman Medical College, Sohar, June 28, 2018
44. Team-based learning. A two-hour workshop for School teachers at Pakistan School Musanna, Musanna, Oman. Nov 3, 2018
45. Team-based learning. 15th CHPE course, SQU, Muscat, Oman, Oct 22-23, 2018
46. Problem-based learning. 15th CHPE course, SQU, Muscat, Oman, Oct 22-23, 2018
47. Workplace based assessment. 15th Student Assessment Workshop, Nov 11-13, 2018 SQU, Muscat, Oman,
48. Advancing management of metastatic ovarian cancer. Standalone symposium arranged by Astra Zeneca, Muscat, Oman, April 30, 2019
49. Critical Appraisal of studies on prognosis, Department of Continuous Professional development, Ministry of Health, Oman, Oct 3, 2019
50. Team-based learning. 16th CHPE course, SQU, Muscat, Oman, Oct 29-31, 2019
51. Teaching in Clinical environment. 16th CHPE course, SQU, Muscat, Oman, Oct 29-31, 2019
52. Introduction to Clinical Assessment 16th Student Assessment Workshop, SQU, Muscat, Oman, Nov 11-13, 2019
53. Workplace based assessment. 16th Student Assessment Workshop, SQU, Muscat, Oman, Nov 11-13, 2019
54. Team-based learning. A two-hour workshop for School teachers at Pakistan School Muscat,

- Muscat, Oman. Dec 7, 2019
55. A case of metastatic prostate cancer. Muscat, Oman. Dec 14, 2019,
 56. Examination Blueprinting, A two-hour workshop for School teachers at Pakistan School Muscat, Muscat, Oman. Dec 21, 2019
 57. Coronavirus: An awareness seminar for general public. Organized by Pakistan Social Club, Oman. Feb 27, 2020
 58. Cytotoxic properties and mechanism of action of Malformin A1: A marine compound from the coast of Oman. Department of Medicine research retreat, Muscat, March 6, 2020
 59. Communication skills. The U project. Webinar, Sept 29, 2020
 60. Fellowship teaching methods. Invited by the postgraduate education organizer. The Heart Center. Oct 5, 2020
 61. 4 C^s required for success in 21st century. College of engineering. Jan 26, 2021.
 62. Man, Mechanics and Machines. College of engineering. Jan 26, 2021.
 63. Artificial Intelligence in Medical Education: A citation-based systematic literature review. Department of Medicine Research retreat. June 15, 2021.
 64. How to write learning objectives. 17th CHPE course, SQU, Muscat, Oman, Sept 19-20, 2021
 65. Team-based learning. 17th CHPE course, SQU, Muscat, Oman, Sept 19-20, 2021
 66. Teaching in Clinical environment. 17th CHPE course, SQU, Muscat, Oman, Sept 19-20, 2021
 67. Introduction to Clinical Assessment 17th Student Assessment Workshop, SQU, Muscat, Oman, Sept 24-26, 2021
 68. Workplace based assessment. 17th Student Assessment Workshop, SQU, Muscat, Oman, Sept 24-26, 2021
 69. Cancer prevention and screening. Training course for Nurses. Comprehensive cancer care Program. SQCCRC. Sept 24, 2021
 70. Basics of Immunology. Training course for Nurses. Comprehensive cancer care Program. SQCCRC. Sept 24, 2021
 71. Immunotherapy in Cancer. Training course for Nurses. Comprehensive cancer care Program. SQCCRC. Sept 24, 2021
 72. Clinical trials. Training course for Nurses. Comprehensive cancer care Program. SQCCRC. Sept 24, 2021
 73. Marine Natural products can overcome resistance to cisplatin in Epithelial Ovarian Cancer. Third GCC Marine Biotechnology Conference, Dec 8-9, 2021, Muscat, Oman (Web-based).
 74. An overview of essential 21st century skills. College of Engineering. SQU. Jan 3, 2022.